```text
Wiki Article
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, represents a valuable scientific substance extensively employed in thrombosis research . This antibody fragment specifically targets the glycoprotein IIb/IIIa complex on thrombocytes , inhibiting clot formation . Consequently , it's commonly applied as a technique to examine the processes underlying thrombosis and to determine the performance of antithrombotic medications . Supply is typically controlled to academic settings.
```
Abciximab Drug Research: Utilizing The C7E3 Fragment and Compound 143653-53-6 in Scientific Assessments
Ongoing investigation into abciximab, a GPIIb/IIIa, frequently utilizes the monoclonal antigen C7E3 and the chemical compound identified as 143653-53-6. These materials are instrumental for investigating abciximab's mode of function, determining its efficacy in various clinical settings, and elucidating potential predictors of therapeutic success. Further investigation leveraging these particular reagents is expected to generate valuable data for enhancing patient care related to cardiovascular disease.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role click here of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Exploring Research Possibilities with this Glycoprotein IIb/IIIa Inhibitor 143653-53-6 and C7E3
Recent research demonstrate that this antiplatelet agent (identified as 143653-53-6) offers significant scientific potential, particularly when associated with a C7E3 construct. Initial observations indicated that this combination might improve therapeutic results in various cardiovascular conditions. Further examination is directed on elucidating the exact process of effect between the antiplatelet medication and C7E3, encompassing study of platelet cohesion and blood vessel preservation.
- Future research work aim to refine administration protocols.
- Preclinical models are being employed to further assess the theories.
- Human assessments are necessary to completely determine patient efficacy.
```
Abciximab (C7E3) for Research: Purity and Details (143653-53-6)
Researchers seeking this antibody for laboratory studies should meticulously assess quality and precise specifications . The compound is typically supplied as a solid powder and detailed analytical information including assessment by LC-MS, potency assays, and endotoxin level testing is available. Verify the supplier's certificate of analysis specifies required ranges for related substances and conforms to relevant quality assurance criteria .
Research-Grade ReoPro Details & Stock
Acquiring analytical-grade Abciximab, specifically referencing the antibody C7E3 and identified by the catalog number 143653-53-6, requires thorough consideration of its origin . This agent is frequently utilized in in vitro studies , particularly those involving platelet clumping and thrombosis . Available suppliers offer this material in varying amounts , typically ranging from g to larger commercial supplies. Please suggest reviewing the documentation of quality to verify integrity and appropriateness for your specific application . Additionally , check the stability date before obtaining to maintain optimal effectiveness.
- Typical Purity: >95%
- Preservation Conditions: -20°C in controlled conditions
- Application : Platelet Clumping Inhibition Studies